FarmaMondo: Bringing Responsible Access Global
With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try…
Intergenerika is Swiss generics association, comprising six companies.
Reimbursable generics achieved sales of 637 million Swiss francs in 2015. Compared with the previous year, the growth amounted to more than seven percent.
The Swiss generics market still has room for further growth and development. In terms of value, the total share of generics within the Swiss pharmaceutical market was 19 percent in 2015 in terms of value, and 32 percent by volume. The member companies of Intergenerika are working hard on the educational front to ensure that pharmacists, doctors and patients have a more balanced view of generics.3
Contact
Telephone +41 61 927 64 08
Altmarktstrasse 96
4410 Liestal
With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try…
Cristina Marti’s colorful and successful career has taken her across Asia from Spain, before settling in Switzerland with Indukern. In this interview, Marti explores themes of competition in Switzerland, the…
Karen Huebscher, CEO of Solvias, a Swiss-headquartered world leader in contract research, development and manufacturing, explains her decision to join the company after a distinguished career at Novartis, the evolution…
Marc Hasler, head of product and market development at Swiss Post, introduces the strategic significance of pharmaceuticals to the company, emerging trends in the logistics industry, and being a flagship…
Jan Denecker, marketing director healthcare at UPS Europe, introduces the logistics heavyweight’s broad portfolio of specialized services for the pharmaceutical industry, the significance of recent M&A activity, and what sets…
Dr. Teodoro Albarano, chief medical officer and vice CEO of Swiss skincare specialists Mavena, discusses why he decided to join the company after an illustrious career in Big Pharma, Mavena’s…
Laurent-Dominique Piveteau, CEO of Swiss medtech innovator Debiotech, discusses digital disruption, Swiss innovation, and future growth drivers. As well as being CEO of Debiotech, you also lecture courses at EPFL…
Alessandro di Napoli, CEO of Swiss family-owned pharmaceutical group, TRB Chemedica, discusses the company’s focus on the rheumatology, ophthalmology and neurology niches and the importance of ‘Swissness’ within its internationalization…
Dr. Raymond De Vré, senior VP and head of Business Operations and Strategy, Biologics at Dr. Reddy’s in Switzerland, discusses scaling up the Indian-headquartered company’s biosimilars business globally and the…
Kurt Reichen, VP Technical Operations at PaxVax, an American-headquartered fully integrated specialty vaccine company focused on infectious diseases, discusses the establishment of the company’s only site outside of the US…
Jürgen Pohle provides both a fascinating and open account of the latest movements of Neovii; a company that possesses the ability to make decisions at the speed of a startup…
Darren Kerr, CEO of Swiss medtech Stratpharma discusses, the company’s roots, its broad portfolio in dermatology, plastic surgery and scar management, as well as its growing international footprint. We…
See our Cookie Privacy Policy Here
